RRS1: A RNA Protein Interaction Regulator for Ribosome Biogenesis

Target Name: RRS1

NCBI ID: G23212

RRS1

RRS1: A RNA Protein Interaction Regulator for Ribosome Biogenesis

The article begins with an introduction to the ribosome, a complex protein structure that is responsible for the production of proteins in living organisms. The ribosome is composed of several subunits, including the alpha-helices, which are responsible for the binding of tRNA molecules with the mRNA template. One of these subunits is RRS1, which is a non-coding RNA molecule that plays a critical role in the regulation of ribosome biogenesis.

RRS1 is a member of the families of RNA-protein interactions (RIS) and is characterized by the presence of a N-terminal alpha-helicle and a C-terminal domain that contains multiple conserved secondary structure elements, including a double-stranded RNA structure and an alternating between GFP and RNA-binding protein (RBP) domains. RRS1 is typically expressed in the cytoplasm of the cell and is involved in various cellular processes, including cell growth, differentiation, and RNA metabolism.

One of the key functions of RRS1 is its role in regulating the biogenesis of the ribosome. The ribosome is the site of the translation of mRNAs, which are derived from the cytoplasmic translation of ribosomal RNA (rRNA) molecules. the assembly of the rRNA molecules into functional subunits and the initiation of the translation process. RRS1 is involved in this process by regulating the assembly and dynamics of the rRNA molecules.

RRS1 has been shown to play a critical role in the regulation of the growth of cancer cells. In many cases, cancer cells exhibit increased ribosome biogenesis, which can lead to the production of large amounts of proteins that contribute to the development and progression of the disease. Therefore, targeting RRS1 with drugs or other therapeutic agents may be a promising strategy for the treatment of cancer.

Another potential application of RRS1 as a drug target is its role in the regulation of cellular aging. As cells age, they undergo a series of changes that are associated with the decline in cellular functionality and the onset of age-related diseases. One of the key factors that contribute to this decline is the dysfunction of the ribosome, which is involved in the production of the proteins that are responsible for maintaining cellular homeostasis and promoting longevity. Therefore, targeting RRS1 with drugs or other therapeutic agents that can modulate its activity may be a promising strategy for the treatment of age-related diseases.

In conclusion, RRS1 is a non-coding RNA molecule that plays a critical role in the regulation of ribosome biogenesis. Its involvement in this process makes it a potential drug target or biomarker for a variety of diseases, including cancer and age-related diseases. Further research is needed to fully understand the mechanisms of RRS1's role in these processes and to develop effective treatments based on its targeting.

Protein Name: Ribosome Biogenesis Regulator 1 Homolog

Functions: Involved in ribosomal large subunit assembly. May regulate the localization of the 5S RNP/5S ribonucleoprotein particle to the nucleolus

The "RRS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RRS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets